Haleon US Capital LLC launched a cash tender for any and all of its outstanding $1.248 billion 3.375% fixed-rate notes due November 2027. The wholly owned subsidiary of Haleon plc is offering par plus accrued interest and a modest premium. The notes trade at roughly 99.8 cents on the dollar. Settlement is expected within ten business days of the early tender deadline.
Haleon inherited the debt structure when it spun out of GSK in July 2022 as the world's largest standalone consumer health company. The $124.8 million tender—roughly 10% of the outstanding principal—suggests selective liability management rather than a full refinancing. The 2027 maturity carries a 3.375% coupon, issued when the US Treasury 5-year was trading near 0.80%. Today that same benchmark sits at 4.35%. The company is paying slightly above par to retire expensive paper early, capturing the arbitrage between its current A- credit rating and the pricing inefficiency left over from the GSK era.
The timing aligns with Haleon's first full fiscal year as an independent entity. The company reported £11.3 billion in revenue for 2023, up 4.8% organically, driven by pricing power in oral care and pain relief categories. Free cash flow reached £2.1 billion, giving management room to optimize the capital structure without disturbing the £1.8 billion share buyback announced in February. The tender also clears runway for a potential euro-denominated issuance in Q2, when the company typically locks in funding for the back half of the year. Haleon's treasury desk has been vocal about reducing dollar exposure and matching liabilities to sterling and euro revenue streams.
Consumer health enjoys structural advantages in the current rate environment—non-cyclical demand, high gross margins above 60%, and brand moats that compress the cost of capital. Haleon trades at 18.2x forward earnings, a 12% discount to Kenvue and 8% discount to Reckitt, despite comparable margin profiles. The market is pricing in integration risk that no longer exists. The tender is a quiet signal that management sees the same mispricing and is willing to deploy cash accordingly.
Allocators should watch for a follow-on debt issuance in April or May, likely in euros, sized between €500 million and €750 million with a 5- to 7-year tenor. The company reports Q1 results on April 24; any commentary on the buyback pace or incremental tenders will clarify whether this is a one-off or the start of a broader liability reshaping. If Haleon prints inside 150 basis points over mid-swaps in Europe, the credit story has flipped.
The debt was issued under a GSK subsidiary. Haleon is buying it back under its own name. That is the only editorial the market needs.